查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552919

醫院感染控制市場規模、佔有率、趨勢分析報告：按類型、最終用途、地區、細分市場預測，2024-2030 年

Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report By Type (Equipment, Services, Consumables), By End Use (Hospitals & ICUs), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

醫院感染控制市場的成長和趨勢

Grand View Research, Inc.的最新報告顯示，到2030年，全球醫院感染控制市場規模預計將達到90.3億美元。

預計 2024 年至 2030 年，該市場將以 5.2% 的複合年成長率擴張。推動市場成長的關鍵因素包括院內感染 (HAI) 發病率上升、政府支持措施和 COVID-19 大流行。 COVID-19 大流行提高了人們對 HAI 的認知和擔憂，並已成為市場的主要催化劑。阻止 COVID-19 傳播的需求也推動了對感染控制設備和用品的需求。

各國政府和監管機構制定了多項政策和準則，以防止交叉污染並保護公眾健康。除了洗手和使用個人防護工具等標準預防措施外，還實施了分流策略、設備提供和適當分配等感染控制標準，以預防醫療機構中的院內感染。特別是，疫情導致個人防護裝備、口罩、消毒劑等消耗品需求激增。

美國衛生與公眾服務部 CDC 開發了一個關於基本感染預防和控制、抗生素抗藥性、設備相關感染、手術相關感染以及疾病/感染的廣泛指南庫，以幫助控制 HAI。大流行結束後，CDC 在其數位圖書館中添加了 COVID-19 感染控制指南。

市場參與企業不斷增加的舉措也促進了市場的成長。這些措施包括策略夥伴關係、併購和產品開發。例如，2021年2月，Getinge擴大了與XPO Logistics的合作關係，後者將為該公司的感染控制業務部門提供從荷蘭到歐洲、中東和非洲地區的倉儲和運輸服務。 2020 年 12 月，Xenex 推出了 LightStrike 6，作為其病原體清除機器人專利系列的一部分。該機器人還可以產生高強度、廣譜紫外線，在兩分鐘內惰性COVID-19 病毒。

醫院感染控制市場報告亮點

  • 消耗品領域佔市場主導地位，2023 年收益佔有率最大，為 46.9%。這是由於醫院和門診醫療中心消耗品的高使用率。 COVID-19 大流行進一步增加了該細分市場的佔有率，因為它增加了對一次性、安全且有效的解決方案來遏制病毒傳播的需求。這包括 N95 口罩、個人防護裝備和手套等產品。
  • 由於醫院和加護病房(ICU) 部門的醫療保健相關感染 (HCAI) 發生率較高，因此 2023 年該部門的收入佔有率最大，為 45.9%。 CDC 估計，每 31 名醫院患者中就有 1 名每天至少患有一次醫院感染。
  • 在亞太地區，由於政府加強推廣抗 HAI 產品，預計未來幾年市場將出現良好成長。
  • 市場參與企業的策略性舉措包括併購、聯盟、地理擴張和新產品開拓。例如，2020年11月，Getinge收購了去污產品製造商Quadralene。該公司已整合到 Getinge 的感染控制產品組合中，擴大了其在手術工作流程業務領域的產品範圍。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 醫院感染控制市場的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 醫院感染控制市場分析工具
    • 波特的分析
    • PESTEL分析

第4章醫院感染控制市場：按類型估計和趨勢分析

  • 細分儀表板
  • 醫院感染控制市場：類型變化分析，2023 年和 2030 年
  • 裝置
  • 服務
  • 消耗品

第5章醫院感染控制市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 醫院感染控制市場：2023 年和 2030 年最終用途變化分析
  • 醫院及加護病房(ICU)
  • 門診手術/診斷中心
  • 其他

第6章 醫院感染控制市場：區域估計與趨勢分析

  • 2023 年及 2030 年醫院感染控制市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • 3M Company
    • Belimed AG
    • O&M Halyards
    • Getinge
    • ASP
    • Sterigenics US, LLC-A Sotera Health Company
    • MMM Group
    • Cantel Medical Corp.（Medivators Inc.）
    • Midmark Corporation
    • STERIS
    • W&H
簡介目錄
Product Code: GVR-4-68039-383-5

Hospital Acquired Infection Control Market Growth & Trends:

The global hospital acquired infection control market size is anticipated to reach USD 9.03 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 5.2% from 2024 to 2030. The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives, and the COVID-19 pandemic. The COVID-19 pandemic has emerged as a major catalyst for the market as it led to increased awareness and concern over HAIs. The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.

Governments and regulatory bodies prescribed several policies and guidelines to prevent cross-contamination and safeguard public health. To prevent nosocomial infections in healthcare facilities, infection control standards were implemented such as triage strategy and provision and proper distribution of equipment, in addition to standard precautions such as hand washing and use of personal protective equipment. In particular, the pandemic resulted in a surge in demand for consumables such as PPE, masks, and disinfectants.

The CDC, of the U.S. Department of Health and Human Services, provides an extensive library of guidelines on basic infection prevention and control, antibiotic resistance, device-associated infections, procedure-associated infections, and disease / organism-specific to promote the control of HAIs. In the wake of the pandemic, the CDC added COVID-19 infection control guidelines to its digital library.

Growing initiatives by market players also contribute to the growth of the market. These initiatives include strategic partnerships, mergers and acquisitions, and product development. In February 2021, for instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company's infection control business unit. In December 2020, Xenex launched LightStrike 6 as part of its patented lineup of pathogen-eliminating robots. The robots produce high-intensity broad-spectrum UV light and can also deactivate the COVID-19 virus in 2 minutes.

Hospital Acquired Infection Control Market Report Highlights:

  • The consumables segment dominated the market and accounted for the largest revenue share of 46.9% in 2023. This was owing to the high usage of consumables in hospitals and ambulatory care centers. The COVID-19 pandemic further contributed to the segment share due to the increased need for disposable, safe, and effective solutions to curb the spread of the virus. These included products such as N95 masks, PPE, and gloves
  • The hospitals and Intensive Care Units (ICUs) segment held the largest revenue share of 45.9% in 2023 due to the high prevalence of healthcare-associated infections (HCAIs) in these facilities. According to CDC estimates, about 1 out of 31 hospital patients suffer from at least one HAI on any given day
  • In Asia Pacific, the market is anticipated to witness lucrative growth in coming years owing to increasing supportive government initiatives to promote HAIs control products in the region
  • Strategic initiatives by market players are mergers and acquisitions, collaboration, geographic expansions, and new product development. For example, in November 2020, Getinge acquired a manufacturer of decontamination products-Quadralene. The company was merged into Getinge's Infection Control portfolio to expand its offerings in the business area of Surgical Workflows

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hospital Acquired Infection Control Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hospital Acquired Infection Control Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1 Bargaining power of the suppliers
      • 3.4.1.2 Bargaining power of the buyers
      • 3.4.1.3 Threats of substitution
      • 3.4.1.4 Threats from new entrants
      • 3.4.1.5 Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1 Political landscape
      • 3.4.2.2 Economic and Social landscape
      • 3.4.2.3 Technological landscape
      • 3.4.2.4 Environmental landscape
      • 3.4.2.5 Legal landscape

Chapter 4. Hospital Acquired Infection Control Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hospital Acquired Infection Control Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Equipment
    • 4.3.1. Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Sterilization Equipment
      • 4.3.2.1 Sterilization Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.2 Heat Sterilization Equipment
        • 4.3.2.2.1. Heat Sterilization Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.2.2. Moist Heat Sterilization
          • 4.3.2.2.2.1. Moist Heat Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.3. Dry Heat Sterilization
        • 4.3.2.3.1. Dry Heat Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 Low Temperature Sterilization
      • 4.3.3.1. Low Temperature Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 Radiation Sterilization
      • 4.3.4.1. Radiation Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 Others
      • 4.3.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Disinfection Equipment
      • 4.3.6.1 Disinfection Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.6.2 Washer Disinfector
        • 4.3.6.2.1 Washer Disinfector Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.7 Flusher Disinfector
      • 4.3.7.1. Flusher Disinfector Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.7.2 Endoscopic Reprocessor Systems
        • 4.3.7.2.1 Endoscopic Reprocessor Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Services
    • 4.4.1. Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Consumables
    • 4.5.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Disinfectants
      • 4.5.2.1 Disinfectants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Sterilization Consumables
      • 4.5.3.1 Sterilization Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hospital Acquired Infection Control Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hospital Acquired Infection Control Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hospitals and Intensive Care Units (ICUs)
    • 5.3.1. Hospitals and Intensive Care Units (ICUs) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Ambulatory Surgical and Diagnostic Centers
    • 5.4.1. Ambulatory Surgical and Diagnostic Centers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hospital Acquired Infection Control Market: Regional Estimates & Trend Analysis

  • 6.1. Hospital Acquired Infection Control Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1 U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa (MEA)
    • 6.6.1. MEA Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. 3M Company
      • 7.4.1.1 Participant's Overview
      • 7.4.1.2 Financial Performance
      • 7.4.1.3 Product Benchmarking
      • 7.4.1.4 Recent Developments/Strategic Initiatives
    • 7.4.2. Belimed AG
      • 7.4.2.1 Participant's Overview
      • 7.4.2.2 Financial Performance
      • 7.4.2.3 Product Benchmarking
      • 7.4.2.4 Recent Developments/Strategic Initiatives
    • 7.4.3. O&M Halyards
      • 7.4.3.1 Participant's Overview
      • 7.4.3.2 Financial Performance
      • 7.4.3.3 Product Benchmarking
      • 7.4.3.4 Recent Developments/Strategic Initiatives
    • 7.4.4. Getinge
      • 7.4.4.1 Participant's Overview
      • 7.4.4.2 Financial Performance
      • 7.4.4.3 Product Benchmarking
      • 7.4.4.4 Recent Developments/Strategic Initiatives
    • 7.4.5. ASP
      • 7.4.5.1 Participant's Overview
      • 7.4.5.2 Financial Performance
      • 7.4.5.3 Product Benchmarking
      • 7.4.5.4 Recent Developments/Strategic Initiatives
    • 7.4.6. Sterigenics U.S., LLC - A Sotera Health Company
      • 7.4.6.1 Participant's Overview
      • 7.4.6.2 Financial Performance
      • 7.4.6.3 Product Benchmarking
      • 7.4.6.4 Recent Developments/Strategic Initiatives
    • 7.4.7. MMM Group
      • 7.4.7.1 Participant's Overview
      • 7.4.7.2 Financial Performance
      • 7.4.7.3 Product Benchmarking
      • 7.4.7.4 Recent Developments/Strategic Initiatives
    • 7.4.8. Cantel Medical Corp. (Medivators Inc.)
      • 7.4.8.1 Participant's Overview
      • 7.4.8.2 Financial Performance
      • 7.4.8.3 Product Benchmarking
      • 7.4.8.4 Recent Developments/Strategic Initiatives
    • 7.4.9. Midmark Corporation
      • 7.4.9.1 Participant's Overview
      • 7.4.9.2 Financial Performance
      • 7.4.9.3 Product Benchmarking
      • 7.4.9.4 Recent Developments/Strategic Initiatives
    • 7.4.10. STERIS
      • 7.4.10.1 Participant's Overview
      • 7.4.10.2 Financial Performance
      • 7.4.10.3 Product Benchmarking
      • 7.4.10.4 Recent Developments/Strategic Initiatives
    • 7.4.11. W&H
      • 7.4.11.1 Participant's Overview
      • 7.4.11.2 Financial Performance
      • 7.4.11.3 Product Benchmarking
      • 7.4.11.4 Recent Developments/Strategic Initiatives